Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
November 11, 2019Presentation of ONCOS-102 melanoma data at SITC Annual Meeting
-
November 7, 2019Targovax ASA: Third quarter 2019 results
-
October 29, 2019Targovax ASA: Invitation to presentation of Targovax’s third quarter 2019 results, Thursday 7 November
-
October 9, 2019Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
Third quarter 2019
Was published on November 7, 2019